Spotlight Growth
No Result
View All Result
Wednesday, March 22, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Galera Therapeutics, Inc. (NASDAQ: GRTX) Reports Phase 3 ROMAN Trial of Avasopasem Met Statistically Significant Primary Endpoint

by admin
December 14, 2021
in Bio/Med/Pharma
0
Galera Therapeutics NASDAQ GRTX Phase 3 ROMAN Trial Avasopasem Spotlight Growth

Galera Therapeutics NASDAQ GRTX Phase 3 ROMAN Trial Avasopasem Spotlight Growth

Galera Therapeutics, Inc. (NASDAQ: GRTX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and commercialization of novel therapeutics to help transform radiotherapy for cancer. Shares of the biopharma company are skyrocketing 105% through early trading on Tuesday, December 14, 2021. Over the past three months, Galera Therapeutics has seen average daily volume of 3.05 million shares. However, volume of 184.7 million shares or dollar volume of around $555.95 million, has already exchanged hands through early trading Tuesday.

Shares of Galera Therapeutics are soaring after the company reported corrected Phase 3 ROMAN trial data of Avasopasem, a treatment for RT-induced severe oral mucositis (SOM) in patients suffering from neck or head cancer. The corrected topline data showed that the trial’s primary endpoint saw statistical significance with its ability to reduce radiotherapy-induced severe oral mucositis. As a result, the FDA has granted Avasopasem Breakthrough Therapy Designation (BTD).

In the corrected results, the treatment group saw a 16% relative reduction of SOM versus the placebo group. Furthermore the treatment group saw a 56% relative reduction in the number of days with SOM compared to the placebo group. Lastly, the treatment group saw 27% less severity of SOM compared to the control group.

Roughly 42,000 patients with head or neck cancer undergo standard radiotherapy each year in the U.S. and are at risk of developing SOM. This causes painful mouth sores that limit the ability to eat and drink. Currently, there are no FDA-approved treatments to reduce the severity or duration of SOM in solid tumors.

“Given the high unmet medical need for patients with head and neck cancer who develop radiotherapy-induced severe oral mucositis, we are gratified that the Phase 3 ROMAN trial achieved statistical significance on the primary endpoint after the correction of the statistical programming error,” said Mel Sorensen, M.D., President and CEO of Galera. “ROMAN is our second randomized trial conducted in patients with head and neck cancer to achieve statistical significance and demonstrate improved clinical benefit. As we continue to analyze the full data set and evaluate our resources, we look forward to meeting with the FDA in 2022 to discuss whether the results from this single Phase 3 trial together with the randomized Phase 2b trial could support an NDA submission.”

Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article, but may choose to initiate a position at any time. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: biopharmaceuticalsbiotechbiotechnology stocksclinical trialscommon stockday tradingemerging growthGalera TherapeuticsGRTXGRTX stockhealth stockshealthcare stocksinvestinginvesting newsinvestmentmedicalmedical stocksmicrocap stocksNASDAQnewspharmaceuticalspublic companyRobinhoodrobinhood armyrobinhood stockssalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtradingtreatmentwebull
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023
U.S. Xpress NYSE USX Knight-Swift Transportation NYSE KNX Acquisition Spotlight Growth

U.S. Xpress Enterprises (NYSE: USX) Enters Into Acquisition Agreement With Knight-Swift Transportation (NYSE: KNX) Valued at $808 Million

March 21, 2023
Axon Enterprise Logo

Axon Enterprise (NASDAQ: AXON) Maintains its Market Dominance with Strong Growth

March 20, 2023
PureCycle Technologies NASDAQ PCT PureFive Distribution Agreement Formerra Spotlight Growth

PureCycle Technologies (NASDAQ: PCT) Enters Into Strategic Distribution Partnership With Formerra For its PureFive UPR Polypropylene Resin Product

March 16, 2023

Recent News

89bio NASDAQ ETNB Phase 2b ENLIVEN Trial Pegozafermin NASH Spotlight Growth

89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

March 22, 2023
U.S. Xpress NYSE USX Knight-Swift Transportation NYSE KNX Acquisition Spotlight Growth

U.S. Xpress Enterprises (NYSE: USX) Enters Into Acquisition Agreement With Knight-Swift Transportation (NYSE: KNX) Valued at $808 Million

March 21, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested